Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for Ataciguat in Moderate calcific aortic valve stenosis (CAVS). The expected timing is based on the latest available company guidance and may change.
KATALYST-AV trial. 11/07/25:- Ph2 data showed ataciguat reduced aortic valve calcium and improved cardiac function/output vs placebo. 06/11/26:- Trial ongoing; 24-wk data in H1 2027 and 48-wk data in H2 2027; Ph3 registrational trial to follow Ph2b enrollment/design work. 08/12/26:- KATALYST-AV Ph2b interim 24-week topline data reiterated for H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.